First Trust Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.75M | Sell |
63,358
-26,905
| -30% | -$1.73M | ﹤0.01% | 1621 |
|
|
2026
Q1 | $5.09M | Buy |
+90,263
| New | +$5.88M | ﹤0.01% | 1428 |
|
|
2025
Q4 | – | Sell |
-53,425
| Closed | -$2.6M | – | 2663 |
|
|
2025
Q3 | $2.6M | Buy |
53,425
+43,651
| +447% | +$2.7M | ﹤0.01% | 1713 |
|
|
2025
Q2 | $729K | Sell |
9,774
-11,216
| -53% | -$743K | ﹤0.01% | 2164 |
|
|
2025
Q1 | $1.33M | Buy |
20,990
+16,792
| +400% | +$1.14M | ﹤0.01% | 1939 |
|
|
2024
Q4 | $328K | Sell |
4,198
-20,663
| -83% | -$1.66M | ﹤0.01% | 2360 |
|
|
2024
Q3 | $2M | Buy |
24,861
+17,188
| +224% | +$1.39M | ﹤0.01% | 1779 |
|
|
2024
Q2 | $635K | Buy |
7,673
+1,412
| +23% | +$124K | ﹤0.01% | 2078 |
|
|
2024
Q1 | $534K | Sell |
6,261
-34,134
| -85% | -$2.68M | ﹤0.01% | 2128 |
|
|
2023
Q4 | $3.45M | Buy |
40,395
+4,070
| +11% | +$352K | ﹤0.01% | 1484 |
|
|
2023
Q3 | $3.25M | Buy |
36,325
+2,140
| +6% | +$191K | ﹤0.01% | 1466 |
|
|
2023
Q2 | $2.91M | Sell |
34,185
-14,389
| -30% | -$1.22M | ﹤0.01% | 1526 |
|
|
2023
Q1 | $4.02M | Sell |
48,574
-8,336
| -15% | -$675K | ﹤0.01% | 1346 |
|
|
2022
Q4 | $4.48M | Buy |
56,910
+49,468
| +665% | +$3.98M | 0.01% | 1248 |
|
|
2022
Q3 | $551K | Sell |
7,442
-1,738
| -19% | -$125K | ﹤0.01% | 2168 |
|
|
2022
Q2 | $598K | Sell |
9,180
-2,375
| -21% | -$141K | ﹤0.01% | 2149 |
|
|
2022
Q1 | $731K | Buy |
11,555
+2,903
| +34% | +$158K | ﹤0.01% | 2146 |
|
|
2021
Q4 | $459K | Buy |
+8,652
| New | +$527K | ﹤0.01% | 2307 |
|
|
2021
Q3 | – | Sell |
-96,475
| Closed | -$6.43M | – | 2561 |
|
|
2021
Q2 | $6.43M | Buy |
96,475
+35,716
| +59% | +$2.53M | 0.01% | 1196 |
|
|
2021
Q1 | $6.75M | Buy |
60,759
+5,433
| +10% | +$672K | 0.01% | 1088 |
|
|
2020
Q4 | $6.57M | Buy |
+55,326
| New | +$5.96M | 0.01% | 986 |
|
|
2020
Q3 | – | Sell |
-22,175
| Closed | -$1.99M | – | 2384 |
|
|
2020
Q2 | $1.99M | Buy |
+22,175
| New | +$2.24M | ﹤0.01% | 1381 |
|
|
2020
Q1 | – | Sell |
-31,284
| Closed | -$3.6M | – | 2387 |
|
|
2019
Q4 | $3.6M | Sell |
31,284
-7,255
| -19% | -$878K | 0.01% | 1249 |
|
|
2019
Q3 | $4.86M | Buy |
+38,539
| New | +$4.89M | 0.01% | 1070 |
|
|
2019
Q2 | – | Sell |
-37,285
| Closed | -$3.26M | – | 2463 |
|
|
2019
Q1 | $3.26M | Sell |
37,285
-2,060
| -5% | -$187K | 0.01% | 1284 |
|
|
2018
Q4 | $3.94M | Sell |
39,345
-10,943
| -22% | -$1.15M | 0.01% | 1085 |
|
|
2018
Q3 | $5.76M | Sell |
50,288
-1,100
| -2% | -$114K | 0.01% | 1056 |
|
|
2018
Q2 | $4.61M | Buy |
+51,388
| New | +$4.34M | 0.01% | 1141 |
|
|
2015
Q3 | – | Sell |
-30,963
| Closed | -$1.28M | – | 2293 |
|
|
2015
Q2 | $1.28M | Buy |
+30,963
| New | +$1.31M | ﹤0.01% | 1706 |
|
|
2015
Q1 | – | Sell |
-14,318
| Closed | -$536K | – | 2260 |
|
|
2014
Q4 | $536K | Sell |
14,318
-1,431
| -9% | -$52.4K | ﹤0.01% | 1961 |
|
|
2014
Q3 | $550K | Sell |
15,749
-486
| -3% | -$17.3K | ﹤0.01% | 1895 |
|
|
2014
Q2 | $573K | Sell |
16,235
-458
| -3% | -$15.3K | ﹤0.01% | 1871 |
|
|
2014
Q1 | $544K | Buy |
16,693
+3,197
| +24% | +$122K | ﹤0.01% | 1900 |
|
|
2013
Q4 | $569K | Buy |
13,496
+7,232
| +115% | +$298K | ﹤0.01% | 1849 |
|
|
2013
Q3 | $250K | Buy |
6,264
+1,115
| +22% | +$46.8K | ﹤0.01% | 2147 |
|
|
2013
Q2 | $213K | Buy |
+5,149
| New | +$208K | ﹤0.01% | 2140 |
|
Other funds holding HAE
AI
First Trust Advisors's HAE Position: Q2 2026 in Review
First Trust Advisors reduced its Haemonetics (HAE) stake by 30% in Q2 2026, selling an estimated $1.73M and leaving 63,358 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1621.
First Trust Advisors first reported a position in HAE in Q2 2013 and has held it in 36 quarters since. The position peaked at $6.75M in Q1 2021. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- First Trust Advisors held 63,358 shares of Haemonetics worth $4.75M as of Q2 2026.
- First Trust Advisors sold 26,905 Haemonetics shares in Q2 2026, an estimated $1.73M.
- Haemonetics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1621 holding.
- First Trust Advisors first reported a position in Haemonetics in Q2 2013 and has held it in 36 quarters since.
- First Trust Advisors's Haemonetics position peaked at $6.75M in Q1 2021.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.